IMOxine (IMO-2055) / Aceragen - LARVOL DELTA

Comparison of Second-Line Treatments for Patients with Platinum-Resistant Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Systematic Review and Bayesian Network Meta-Analysis. (PubMed, Cancers (Basel)) - "These studies compared 20 different treatments, including the standard of care (SOC: docetaxel, methotrexate, or cetuximab), PD-1 inhibitors (nivolumab or pembrolizumab), durvalumab, tremelimumab, durvalumab + tremelimumab, palbociclib + SOC, tivantinib + SOC, sorafenib + SOC, EMD1201081 + SOC, vandetanib + SOC, PX-866 + SOC, 5-fluorouracil + SOC, cixutumumab + SOC, gefitinib + SOC, cabazitaxel, nolatrexed, duligotuzumab, zalutumumab, gefitinib, and afatinib. Afatinib presented a better PFS and ORR than the SOC. Compared with afatinib, the PD-1 inhibitor had a better OS but a worse PFS."

Journal • Retrospective data • Review • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Idera Pharmaceuticals reports first quarter 2012 financial results (Idera Pharmaceuticals, Inc) - Idera Pharmaceuticals announced top-line data from a P1b trial of IMO-2055 in combination with Tarceva & Avastin for the treatment of NSCLC; Company also announced top-line from a P2 trial of IMO-2055 in combination with Erbitux in Second-Line Erbitux-naïve subjects with recurrent or metastatic SCCHN; Anticipated detailed data from both the trials are expected at a medical conference in the Q2 2012

Anticipated data presentation • Non Small Cell Lung Cancer • Oncology